A New Strategy for the Identification of Novel Molecules with Targeted Proresolution of Inflammation Properties
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
As our understanding of inflammatory resolution increases, drugs that trigger proresolution pathways may become significant in treating chronic inflammatory diseases. However, anti-inflammatory drugs are traditionally tested during the first hours of onset (i.e., to dampen leukocyte and edema formation), and their ability to trigger proresolution processes has never been investigated. Moreover, there is no model available to screen for putative proresolving agents. In this study, we present a new strategy to identify therapeutics for their ability to switch inflammation off and restore homeostasis. Injecting 1.0 mg of zymosan i.p. causes transient inflammation characterized by polymorphonuclear neutrophil clearance and dominated by recently described resolution-phase macrophages along with an innate-type lymphocyte repopulation, the latter being a marker of tissue homeostasis. In contrast, 10 mg of zymosan elicits an aggressive response characterized by classically activated macrophages leading to systemic inflammation and impaired lymphocyte repopulation. Although this latter model eventually resolves, it nonetheless represents inflammation in the clinically relevant setting of polymorphonuclear neutrophil/classically activated macrophage dominance driving a cytokine storm. Treating such a reaction therapeutically with proresolution drugs provides quantifiable indices of resolution—polymorphonuclear neutrophil/macrophage clearance, macrophage phenotype switching (classically activated to resolution phase), and repopulation with resolution-phase lymphocytes—cardinal signs of inflammatory resolution and homeostasis in the peritoneum. As an illustration, mice bearing peritonitis induced by 10 mg of zymosan- were given ibuprofen, resolvin E1, a prostaglandin D2 receptor 1 agonist, dexamethasone, rolipram, or azithromycin, and their ability to trigger resolution and homeostasis in this new inflammatory setting was investigated. We present the first model for testing drugs with targeted proresolution properties using quantifiable parameters of inflammatory resolution and homeostasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resolution of inflammation: the beginning programs the end
Serhan, C. N., & Savill, J. (2005) · Nature Immunology · doi:10.1038/ni1276 · Cited by 2,552
Resolution of in flammation: state of the art, definitions and terms
Serhan, C. N., Brain, S. D., Buckley, C. D., Gilroy, D. W., Haslett, C., O'Neill, L. A. J., Perretti, M., Rossi, A. G., & Wallace, J. L. (2007) · The FASEB Journal · doi:10.1096/fj.06-7227rev · Cited by 1,045 · cited 1×
“Indeed, it would also give some insight into molecules that exert so-called resolution-toxic effects (3), because molecules that unwittingly impair resolution may be highlighted more readily than if the model with 10 mg of zymosan is used.”
BackgroundSelf-citationHurst, S. M., Wilkinson, T. S., McLoughlin, R. M., Jones, S., Horiuchi, S., Yamamoto, N., Rose-John, S., Fuller, G. M., Topley, N., & Jones, S. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00151-0 · Cited by 811 · cited 1×
“0 mg of zymosan), peritoneal inflammation normally resolves between 24 and 72 h and is characterized by cytokine and chemokine clearance (14), a transition in populations of PMNs to predominantly macrophages (15), apoptosis and phagocytosis (16), cyclooxygenase/LOX-derived lipid biosynthesis (17), rM macrophages (9),…”
BackgroundMolecular Circuits of Resolution: Formation and Actions of Resolvins and Protectins
Bannenberg, G. L., Chiang, N., Ariel, A., Arita, M., Tjonahen, E., Gotlinger, K. H., Hong, S., & Serhan, C. N. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.4345 · Cited by 699
Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes
Liu, Y., Cousin, J. M., Hughes, J., Van Damme, J., Seckl, J. R., Haslett, C., Dransfield, I., Savill, J., & Rossi, A. G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.6.3639 · Cited by 299
Cited by
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041
Resolvins and protectins in inflammation resolution
Serhan, C. N., & Petasis, N. A. (2011) · Chemical Reviews · doi:10.1021/cr100396c · Cited by 996
Infection regulates pro-resolving mediators that lower antibiotic requirements
Chiang, N., Fredman, G., Bäckhed, F., Oh, S. F., Vickery, T., Schmidt, B. A., & Serhan, C. N. (2012) · Nature · doi:10.1038/nature11042 · Cited by 664
Azithromycin: Mechanisms of action and their relevance for clinical applications
Parnham, M. J., Haber, V. E., Giamarellos-Bourboulis, E. J., Perletti, G., Verleden, G. M., & Vos, R. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.003 · Cited by 661
The resolution of inflammation
Buckley, C. D., Gilroy, D. W., Serhan, C. N., Stockinger, B., & Tak, P. P. (2013) · Nature Reviews Immunology · doi:10.1038/nri3362 · Cited by 560
Self-citation
Metadata
- Authors
- Navarro-Xavier, R. A., Newson, J., Silveira, V. L. F., Farrow, S. N., Gilroy, D. W., & Bystrom, J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-12-23
- Volume
- 184
- Issue
- 3
- Pages
- 1516-1525
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1583416473
- Cited by
- 100
- References
- 5
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A New Strategy for the Identification of Novel Molecules with Targeted Proresolution of Inflammation Properties. https://app.cochat.ai/papers/10.4049/jimmunol.0902866
- The paper
- Navarro-Xavier, R. A., Newson, J., Silveira, V. L. F., Farrow, S. N., Gilroy, D. W., & Bystrom, J. (2010). A New Strategy for the Identification of Novel Molecules with Targeted Proresolution of Inflammation Properties. The Journal of Immunology. https://doi.org/10.4049/jimmunol.0902866
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.